Cited by 1,317Cancer Genomics and DiagnosticsPancreatic and Hepatic Oncology ResearchChromatin Remodeling and Cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

Open access

Campbell, Peter J., Yachida, Shinichi, Mudie, Laura J., Stephens, Philip J., Pleasance, Erin D., Stebbings, Lucy A., Morsberger, Laura A., Latimer, Calli, McLaren, Stuart, Lin, Meng-Lay, McBride, David J., Varela, Ignacio, Nik-Zainal, Serena A., Leroy, Catherine, Jia, Mingming, Menzies, Andrew, Butler, Adam P., Teague, Jon W., Griffin, Constance A., Burton, John, Swerdlow, Harold, Quail, Michael A., Stratton, Michael R., Iacobuzio-Donahue, Christine, Futreal, P. Andrew·2010·Nature

DOI 10.1038/nature09460PMC PMC3137369

Open this paper in CoChat — free account

Abstract

Pancreatic cancer is an aggressive malignancy with a five-year mortality of 97-98%, usually due to widespread metastatic disease. Previous studies indicate that this disease has a complex genomic landscape, with frequent copy number changes and point mutations, but genomic rearrangements have not been characterized in detail. Despite the clinical importance of metastasis, there remain fundamental questions about the clonal structures of metastatic tumours, including phylogenetic relationships among metastases, the scale of ongoing parallel evolution in metastatic and primary sites, and how the tumour disseminates. Here we harness advances in DNA sequencing to annotate genomic rearrangements in 13 patients with pancreatic cancer and explore clonal relationships among metastases. We find that pancreatic cancer acquires rearrangements indicative of telomere dysfunction and abnormal cell-cycle control, namely dysregulated G1-to-S-phase transition with intact G2-M checkpoint. These initiate amplification of cancer genes and occur predominantly in early cancer development rather than the later stages of the disease. Genomic instability frequently persists after cancer dissemination, resulting in ongoing, parallel and even convergent evolution among different metastases. We find evidence that there is genetic heterogeneity among metastasis-initiating cells, that seeding metastasis may require driver mutations beyond those required for primary tumours, and that phylogenetic trees across metastases show organ-specific branches. These data attest to the richness of genetic variation in cancer, brought about by the tandem forces of genomic instability and evolutionary selection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09460

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citation
Mapping short DNA sequencing reads and calling variants using mapping quality scores
Li, H., Ruan, J., & Durbin, R. (2008) · Genome Research · doi:10.1101/gr.078212.108 · Cited by 2,638
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
A comprehensive catalogue of somatic mutations from a human cancer genome
Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., Varela, I., Lin, M.-L., Ordóñez, G. R., Bignell, G. R., et al. (2010) · Nature · doi:10.1038/nature08658 · Cited by 1,696
Self-citation
THE STABILITY OF BROKEN ENDS OF CHROMOSOMES IN ZEA MAYS
McClintock, B. (1941) · Genetics · doi:10.1093/genetics/26.2.234 · Cited by 1,605
Pancreatic cancer biology and genetics
Bardeesy, N. M., & DePinho, R. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc949 · Cited by 1,175
Parallel progression of primary tumours and metastases
Klein, C. A. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2627 · Cited by 1,161
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,144
A small-cell lung cancer genome with complex signatures of tobacco exposure
Pleasance, E., Stephens, P. J., O’Meara, S., McBride, D. J., Meynert, A. M., Jones, D., Lin, M., Beare, D. M., Lau, K. W., Greenman, C., et al. (2009) · Nature · doi:10.1038/nature08629 · Cited by 1,076
Self-citation
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
Shah, S. P., Morin, R. D., Khattra, J. S., Prentice, L., Pugh, T. J., Burleigh, A., Delaney, A. D., Gelmon, K. A., Guliany, R., Senz, J., et al. (2009) · Nature · doi:10.1038/nature08489 · Cited by 1,063

Flagged first, then by citations

Show all 30 references

Sorted by citations

Items 901–1,000 of 1,000

A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis
Kim, S. J., Chang, S., Lee, Y., Kim, N. Y., Hwang, Y., Min, H. J., Yoo, K.-S., Park, E. H., Kim, S., Chung, Y.-H., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.056 · Cited by 10
Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient
Cotterell, J. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s45232 · Cited by 10
Genetic Profiling of Cancers of the Digestive System: Biological Insights and Clinical Implications
Stenzinger, A., & Weichert, W. (2017) · Pathobiology · doi:10.1159/000446545 · Cited by 10
High-depth sequencing of paired primary and metastatic tumours: Implications for personalised medicine
Grellety, T., Lucchesi, C., Hostein, I., Auzanneau, C., Khalifa, E., Soubeyran, I., & Italiano, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.019 · Cited by 10
Clinical Interest of Circulating Tumor DNA in Oncology
Franczak, C., Filhine-Trésarrieu, P., Broséus, J., Gilson, P., Merlin, J., & Harlé, A. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2018.10.007 · Cited by 10
Spatial UBE2N protein expression indicates genomic instability in colorectal cancers
Gemoll, T., Miroll, E., Klein, O., Lischka, A., Eravci, M., Thorns, C., & Habermann, J. K. (2019) · BMC Cancer · doi:10.1186/s12885-019-5856-1 · Cited by 10
Long noncoding RNA LINC00261 upregulates ITIH5 to impair tumorigenic ability of pancreatic cancer stem cells
Zou, L., He, H., Li, Z., Chen, O., Jia, X., & Zhang, H. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00575-0 · Cited by 10
Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases
Qorri, B., Mokhtari, R. B., Harless, W. W., & Szewczuk, M. R. (2022) · Cancers · doi:10.3390/cancers14153595 · Cited by 11
Transflip mutations produce deletions in pancreatic cancer
Norris, A. L., Kamiyama, H., Makohon-Moore, A. P., Pallavajjala, A., Morsberger, L. A., Lee, K., Batista, D., Iacobuzio–Donahue, C. A., Lin, M., Klein, A. P., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22258 · Cited by 10
Self-citation
Prediction of the Number of Activated Genes in Multiple Independent Cd+2- and As+3-Induced Malignant Transformations of Human Urothelial Cells (UROtsa)
Garrett, S. H., Somji, S., Sens, D. A., & Zhang, K. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085614 · Cited by 10
Challenges in developing small-molecule quadruplex therapeutics
Neidle, S. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.05.005 · Cited by 11
KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer
Yachida, S., Yoshinaga, S., Shiba, S., Urabe, M., Tanaka, H., Takeda, Y., Shimizu, A., Sakamoto, Y. S., Hijioka, S., Haba, S., et al. (2025) · Annals of Surgery · doi:10.1097/sla.0000000000006645 · Cited by 9
Self-citation
Extrachromosomal DNA: shaping the evolutionary dynamics of cancer
Haughey, M. J., Noorani, I., Swanton, C., Mischel, P. S., & Werner, B. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.06.004 · Cited by 9
Chimeric antigen receptor T cells therapy in solid tumors
Rababah, F., Alabduh, T., Awawdeh, A., Shatnawi, T., AL-shdaifat, M., Ibdah, E., Shatnawi, S., AbuZetun, Y. I., Helaly, A. M., & Ghorab, D. S. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03122-8 · Cited by 9
Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions
Palma, A. M., Vudatha, V., Peixoto, M. L., & Madan, E. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.005 · Cited by 10
Genomic Biomarkers For Patient Selection And Stratification: The Cancer Paradigm
Moschos, S. A. (2012) · Bioanalysis · doi:10.4155/bio.12.241 · Cited by 9
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials
Lopez, J. S., Harris, S., Roda, D., & Yap, T. A. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30533 · Cited by 9
Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions
Nagawkar, S. S., Abu-Funni, S., Simon, E., Bick, T., Prinz, E., Sabo, E., Ben‐Izhak, O., & Hershkovitz, D. (2015) · Pancreas · doi:10.1097/mpa.0000000000000562 · Cited by 9
TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study
Kamiza, A. B., Hsieh, L.-L., Tang, R., Chien, H., Lai, C., Chiu, L.-L., Lo, T.-P., Hung, K., You, J., Wang, W., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167354 · Cited by 9
Sequencing Brain Metastases and Opportunities for Targeted Therapies
Chukwueke, U. N., & Brastianos, P. K. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0170 · Cited by 9
Array comparative genomic hybridization of 18 pancreatic ductal adenocarcinomas and their autologous metastases
Rausch, V., Krieg, A. H., Camps, J., Behrens, B., Beier, M., Wangsa, D., Heselmeyer‐Haddad, K., Baldus, S. E., Knoefel, W. T., Ried, T., et al. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2886-0 · Cited by 9
Nanotechnology for cancer therapy
Patil, K., & Yakhmi, J. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-42863-7.00013-x · Cited by 9
Biologie des métastases et mécanismes moléculaires de leur formation
Coussy, F., Bonin, F., Azorin, P., Tariq, Z., & Driouch, K. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.11.010 · Cited by 12
Clonal dominance defines metastatic dissemination in pancreatic cancer
Ho, I.-L., Li, C.-Y., Wang, F., Zhao, L., Liu, J., Yen, E.-Y., Dyke, C. A., Shah, R., Liu, Z., Çetin, A. O., et al. (2024) · Science Advances · doi:10.1126/sciadv.add9342 · Cited by 9
Self-citation
Molecular Pathology of Cancer Metastasis: Suggestions for Future Therapy
Angelucci, A., & Alesse, E. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_18 · Cited by 9
Anti‐tumor effects of endogenous prostate cancer‐specific CD8 T cells in a murine TCR transgenic model
Bruno, T. C., Rothwell, C. C., Grosso, J. F., Getnet, D., Yen, H., Durham, N. M., Netto, G. J., Pardoll, D. M., & Drake, C. G. (2011) · The Prostate · doi:10.1002/pros.21453 · Cited by 9
Real-Time Monitoring of miRNA Function in Pancreatic Cell Lines Using Recombinant AAV-Based miRNA Asensors
Chen, J., Liu, X., Xue, C., Guo, Z., Liu, J., Hao, J., & Zhang, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066315 · Cited by 9
Elevated DNA damage response in pancreatic cancer
Osterman, M. D., Kathawa, D., Liu, D., Guo, H., Zhang, C., Li, M., Yu, X., & Li, F. (2014) · Histochemistry and Cell Biology · doi:10.1007/s00418-014-1245-7 · Cited by 10
Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression
Durante, S., Vecchiarelli, S., Astolfi, A., Grassi, E., Casadei, R., Santini, D., Panzacchi, R., Ricci, C., Serravalle, S., Tarantino, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11501 · Cited by 9
Tumor Heterogeneity
Cassidy, J. W., & Bruna, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00004-7 · Cited by 9
Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma
Keane, F., Saadat, L. V., O'Connor, C. A., Chou, J. F., Bowman, A. S., Xu, F., Crowley, F., Debnath, N., Schoenfeld, J. D., Singhal, A., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf139 · Cited by 10
ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass
Jansen, R., Möhlendick, B., Bartenhagen, C., Tóth, C., Lehwald, N., Stoecklein, N. H., Knoefel, W. T., & Lachenmayer, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-28941-6 · Cited by 8
Targeting Genome Stability in Melanoma—A New Approach to an Old Field
Osrodek, M., & Woźniak, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073485 · Cited by 11
Insight into the Basic Mechanisms and Various Modulation Strategies Involved in Cancer Drug Resistance
Yadav, D., Rao, G. S. N. K., Paliwal, D., Singh, A., & Shadab, S. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230508110258 · Cited by 8
Characterization of Two Novel Cell Lines with Distinct Heterogeneity Derived from a Single Human Bile Duct Carcinoma
Wang, J., Li, L., Zhang, K., Yu, Y., Li, B., Li, J., Yan, Z., Hu, Z., Yen, Y., Wu, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054377 · Cited by 8
Metastatic disease: A drug discovery perspective
Lehembre, F., & Regenass, U. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.03.005 · Cited by 8
Cancer Genetics and Implications for Clinical Management
Jamieson, N. B., Chang, D. K.-F., & Biankin, A. V. (2015) · Surgical Clinics of North America · doi:10.1016/j.suc.2015.05.003 · Cited by 8
Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model
Yeo, D., Huynh, N. T., Beutler, J. A., Baldwin, G. S., He, H. Z., & Nikfarjam, M. (2016) · Journal of Investigative Surgery · doi:10.3109/08941939.2016.1160167 · Cited by 8
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy
Gits, H. C., Tang, A., Harmsen, W. S., Bamlet, W. R., Graham, R. P., Petersen, G. M., Smyrk, T. C., Mahipal, A., Kowalchuk, R. O., Ashman, J. B., et al. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-55 · Cited by 7
Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma
Matsushita, K., Kobayashi, S., Akita, H., Konno, M., Asai, A., Noda, T., Iwagami, Y., Asaoka, T., Gotoh, K., Mori, M., et al. (2021) · Cancer Reports · doi:10.1002/cnr2.1582 · Cited by 8
Emerging Role for 7T MRI and Metabolic Imaging for Pancreatic and Liver Cancer
Rivera, D. S. (2022) · Metabolites · doi:10.3390/metabo12050409 · Cited by 8
Analysis of M2 macrophage-associated risk score signature in pancreatic cancer TME landscape and immunotherapy
Yang, D., Zhao, F., Yang, S., Zhou, Y., Shen, J., Zhao, K., & Ding, Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1184708 · Cited by 8
Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions
Cavaleri, F., Chattopadhyay, S., Palsule, V. V., Kar, P. K., & Chatterjee, R. (2024) · Integrative Cancer Therapies · doi:10.1177/15347354231223499 · Cited by 8
Spontane Malignitätsänderung bei soliden Malignomen
Stelzner, F. (2012) · Der Chirurg · doi:10.1007/s00104-011-2236-z · Cited by 8
Gene Signatures of Genomic Instability as Prognostic Tools for Breast Cancer
Sansregret, L., & Nepveu, A. (2011) · Future Oncology · doi:10.2217/fon.11.34 · Cited by 8
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Fox, A. J., Hiemenz, M., Lieberman, D. B., Sukhadia, S., Li, B., Grubb, J., Candrea, P., Ganapathy, K., Zhao, J., Roth, D. B., et al. (2016) · Journal of Visualized Experiments · doi:10.3791/52758 · Cited by 8
The genomic dynamics during progression of lung adenocarcinomas
Yang, B., Luo, L., Luo, W., Zhou, Y., Yang, C., Xiong, T., Li, X., Meng, X., Li, L., Zhang, X., et al. (2017) · Journal of Human Genetics · doi:10.1038/jhg.2017.40 · Cited by 8
Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers
Corsini, E. M., Wang, J., Wu, C.-C., Fujimoto, J., Negrao, M. V., Chen, R., Quek, K., Mitchell, K. G., Chow, C.-W. B., Little, L., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1 · Cited by 8
Self-citation
Clever Leukemic Stem Cells Branch Out
Vyas, P., & Jacobsen, S. E. W. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.02.015 · Cited by 8
Further genetic diversification in multiple tumors and an evolutionary perspective on therapeuticsPreprint
Tao, Y., Hu, Z., Ling, S., Yeh, S., Zhai, W., Chen, K., Li, C., Wang, Y., Wang, K., Wang, H., et al. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/025429 · Cited by 8
Metabolic vulnerability of cancer stem cells and their niche
Marrone, L., Romano, S., Malasomma, C., Giacomo, V. D., Cerullo, A., Abate, R., Vecchione, M. A., Fratantonio, D., & Romano, M. F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1375993 · Cited by 7
Reciprocal tumor‐platelet interaction through the EPHB1‐EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adenocarcinoma
Yao, L., Qin, W., Hu, L., Shi, T., Yang, J. Y., Li, Q., Nie, H., Li, J., Wang, X., Zhu, L., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12637 · Cited by 7
Multidimensional analyses identify genes of high priority for pancreatic cancer research
Nwosu, Z. C., Giza, H. M., Nassif, M., Charlestin, V., Menjivar, R. E., Kim, D.-H., Kemp, S. B., Sajjakulnukit, P., Andren, A. C., Zhang, L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174264 · Cited by 9
Using Systems Biology to Understand Cancer as an Evolutionary Process
Pepper, J. W., Dunn, B. K., Fagerstrom, R. M., Gohagan, J. K., & Vydelingum, N. (2014) · Journal of Evolutionary Medicine · doi:10.4303/jem/235678 · Cited by 7
Identification of genomic instability related lncRNA signature with prognostic value and its role in cancer immunotherapy in pancreatic cancer
Zhu, X., Yu, R., Peng, Y., Miao, Y., Jiang, K., & Li, Q. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.990661 · Cited by 7
Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review
Ruff, S. M., & Pawlik, T. M. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2903101 · Cited by 7
Clonal expansion in normal tissues
Maeda, H., & Kakiuchi, N. (2024) · Cancer Science · doi:10.1111/cas.16183 · Cited by 7
The Personalization of Therapy: Molecular Profiling Technologies and Their Application
Zerón-Medina-Cuairán, J., de Olza, M. O., Braña, I., & Rodon, J. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.026 · Cited by 7
Ultradeep analysis of tumor heterogeneity in regions of somatic hypermutation
Spence, J. M., Spence, J. P., Abumoussa, A. L., & Burack, R. (2015) · Genome Medicine · doi:10.1186/s13073-015-0147-1 · Cited by 7
Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
Bianconi, D., Heller, G., Spies, D., Herac, M., Gleiß, A., Liebmann‐Reindl, S., Unseld, M., Kieler, M., Scheithauer, W., Streubel, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04743-0 · Cited by 7
Evaluation of functional and bioactive properties of crude gill extract of Tor putitora using different assays
Rehman, G., Sardar, S., Alkhateeb, M. A., Mohamed, R. A. E. H., Galil, F. M. A. A., Hamayun, M., Shahjeer, K., Iqbal, T., Ahmed, N., Nawaz, T., et al. (2022) · International Journal of Food Science & Technology · doi:10.1111/ijfs.15961 · Cited by 7
Differential modulation of cellular phenotype and drug sensitivity by extracellular matrix proteins in primary and metastatic pancreatic cancer cells
Usman, O. H., Kumar, S., Walker, R. R., Xie, G., Sumajit, H. C., Jalil, A. R., Ramakrishnan, S., Dooling, L. J., Wang, Y. J., & Irianto, J. (2023) · Molecular Biology of the Cell · doi:10.1091/mbc.e23-02-0075 · Cited by 7
Cancer genomics and pathology: All Together Now
Shibata, T. (2012) · Pathology International · doi:10.1111/j.1440-1827.2012.02855.x · Cited by 7
Adjuvant therapy for pancreas adenocarcinoma: where are we going?
O'Reilly, E. M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.232 · Cited by 7
Biology, pathophysiology, and epidemiology of pancreatic cancer
Dariya, B., Alam, A., & Nagaraju, G. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819457-7.00001-3 · Cited by 7
Engineered tumor models for cancer biology and treatment
Moon, H., & Han, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102983-1.00015-6 · Cited by 7
Pancreatic adenocarcinoma with histologically proven portal vein infiltration: what is the outcome?
Martin, D. J., Petermann, D., Fontanella, S., Yan, P., Halkic, N., Demartines, N., & Schäfer, M. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001266 · Cited by 7
From lab to life: technological innovations in transforming cancer metastasis detection and therapy
Basu, S., Sasikumar, S., Sur, S., Vaidya, V., Kheur, S. M., Gupta, S., Ranjan, A., Paul, M. K., Nawani, N. N., Bhat, A., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02910-8 · Cited by 7
Radiomics and machine learning analysis of liver magnetic resonance imaging for prediction and early detection of tumor response in colorectal liver metastases
Yoon, S., Kim, Y. J., Jeon, J. S., Ahn, S. J., & Choi, S. J. (2024) · Korean Journal of Clinical Oncology · doi:10.14216/kjco.24005 · Cited by 7
Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Semenuk, M. A., Veenstra, T. D., Georgevich, G., Rochman, M., Gusev, Y., Haanes, E. J., Bogunovic, B. M., Lebowitz, M., Daraselia, N., & Schwartz, E. I. (2011) · Recent Patents on Biomarkerse · doi:10.2174/2210309011101030222 · Cited by 6
Präzisionsonkologie und molekulare Tumorboards – Konzepte, Chancen und Herausforderungen
Holch, J. W., Westphalen, C. B., Hiddemann, W., Heinemann, V., Jung, A., & Metzeler, K. H. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-120717 · Cited by 5
Polo-like kinase 1 is involved in apoptosis, invasion, and metastasis of pancreatic ductal adenocarcinoma
Mao, Y., Xi, L., Li, Q., Zhang, X., & Yu, C. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1019 · Cited by 7
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Fox, A. J., Hiemenz, M., Lieberman, D. B., Sukhadia, S., Li, B., Grubb, J., Candrea, P., Ganapathy, K., Zhao, J., Roth, D. B., et al. (2016) · Journal of Visualized Experiments · doi:10.3791/52758-v · Cited by 6
Epigenomic interplay in tumor heterogeneity: Potential of epidrugs as adjunct therapy
Rath, S., Chakraborty, D., Pradhan, J., Khan, M. I., & Dandapat, J. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155967 · Cited by 6
Establishment, characterization, and biobanking of 36 pancreatic cancer organoids: prediction of metastasis in resectable pancreatic cancer
Kim, S., Seo, H., Lee, J.-O., Maeng, J. E., Shin, Y., Lee, S. H., Jang, J., & Ku, J. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00939-5 · Cited by 6
External assessment of the Early Mortality Risk Score in patients with adenocarcinoma undergoing pancreaticoduodenectomy
Joliat, G., Petermann, D., Demartines, N., & Schäfer, M. (2015) · HPB · doi:10.1111/hpb.12422 · Cited by 6
Clinical and molecular characterization of an infant with a tandem duplication and deletion of 19p13
Tan, R. N. G. B., Witlox, R. S. G. M., Hilhorst‐Hofstee, Y., Peeters‐Scholte, C. M. P. C. D., den Hollander, N. S., Ruivenkamp, C. A. L., Hoffer, M. J. V., Hansson, K. B. M., van Roosmalen, M. J., Kloosterman, W. P., et al. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37076 · Cited by 6
Integrative cancer genomics: models, algorithms and analysis
Chen, J., & Zhang, S. (2016) · Frontiers of Computer Science · doi:10.1007/s11704-016-5568-5 · Cited by 7
Studying the Role of Chromosomal Instability (CIN) in GI Cancers Using Patient-derived Organoids
Patil, S., Jahagirdar, S., Khot, M., & Sengupta, K. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167256 · Cited by 6
Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution
Monberg, M. E., Geiger, H. M., Lee, J. J., Sharma, R., Semaan, A., Bernard, V., Wong, J., Wang, F., Liang, S., Swartzlander, D. B., et al. (2022) · RePEc: Research Papers in Economics · Cited by 6
Ductal adenocarcinoma of the pancreas usually retained SMAD4 and p53 protein status as well as expression of epithelial-to-mesenchymal transition markers and cell cycle regulators at the stage of liver metastasis
Liszka, Ł. (2014) · Polish Journal of Pathology · doi:10.5114/pjp.2014.43959 · Cited by 6
Cancer stem cells and addicted cancer cells
Logtenberg, M. E. W., & Boonstra, J. (2013) · Oncology Discovery · doi:10.7243/2052-6199-1-7 · Cited by 6
Developments in oligometastatic hormone-sensitive prostate cancer
Chow, K., McCoy, P. J., Stuchbery, R., Corcoran, N. M., & Hovens, C. M. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2542-x · Cited by 6
Weighted Gene Co-Expression Network Analysis Reveals Six Hub Genes Involved in and Tight Junction Function in Pancreatic Adenocarcinoma and their Potential Use in Prognosis
Xia, W., Zhang, L.-H., & Liu, Y. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2019.0122 · Cited by 6
Tropism between hepatic and pulmonary metastases in colorectal cancers
Kim, S.-H., Choi, S., Park, J. S., Lee, J., Cho, Y. B., Kang, M., Lee, W. Y., Choi, Y. S., Kim, H. K., Han, J., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1837 · Cited by 6
The Darwinian Dynamics of Motility and Metastasis
Schiffman, J. D., White, R. M., Graham, T. A., Huang, Q., & Aktipis, A. (2016) · doi:10.1007/978-1-4939-6460-4_8 · Cited by 6
Mechanisms Underpinning Osteosarcoma Genome Complexity and EvolutionPreprint
Valle-Inclán, J. E., Noon, S. D., Trevers, K. E., Elrick, H., Tanguy, M., Butters, T., Muyas, F., Amary, F. M., Tirabosco, R., Giess, A. P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.29.573403 · Cited by 6
Oncogene alterations in non-small cell lung cancer with FGFR1 amplification—novel approach to stratify patients who benefit from FGFR inhibitors
Kitai, H., & Ebi, H. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-777 · Cited by 6
Phenotypic, Genomic, and Transcriptomic Heterogeneity in a Pancreatic Cancer Cell Line
Xie, G., Zhang, L., Usman, O. H., Kumar, S., Modak, C., Patel, D., Kavanaugh, M., Mallory, X., Wang, Y. J., & Irianto, J. (2024) · Pancreas · doi:10.1097/mpa.0000000000002371 · Cited by 5
The molecular logic of early metastasis in pancreatic cancer: crosstalk between tumor and microenvironment
Costamagna, A., Noemi, G., & Martini, M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1726581 · Cited by 7
A breakage–replication/fusion process explains complex rearrangements and segmental DNA amplification
Zhang, C., Mendez‐Dorantes, C., Burns, K. H., & Pellman, D. S. (2026) · Nature Genetics · doi:10.1038/s41588-025-02434-5 · Cited by 8
Gene signatures from pancreatic cancer tumor and stromal cells predict disease outcome
Kottakis, F., & Bardeesy, N. M. (2015) · Nature Genetics · doi:10.1038/ng.3408 · Cited by 5
Blood-Based Biomarkers in the Diagnosis and Risk Stratification of Pancreatic Cysts
Peller, M. T., & Das, K. K. (2023) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2023.03.009 · Cited by 5
DNA Damage, Repair and Misrepair in Cancer and in Cancer Therapy
Ana, M., Ferreira, L. M. R., Joana, F., Carlos, F., & Maria, C. (2011) · InTech eBooks · doi:10.5772/23190 · Cited by 5
The right time, the right place: will targeting human cancer-associated mutations to the mouse provide the perfect preclinical model?
Blyth, K., Morton, J. P., & Sansom, O. J. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.009 · Cited by 5
(R)Evolutionary Therapy: The Potential of Immunotherapy to Fulfill the Promise of Personalized Cancer Treatment
Madan, R. A., & Gulley, J. L. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju347 · Cited by 5
Genomics-Based Cancer Theranostics
Yin, Z., Mancuso, J. J., Li, F., & Wong, S. T. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407722-5.00002-5 · Cited by 5
Tumor Dormancy, Quiescence, and Senescence, Volume 1
Hayat, M. A. (2013) · Springer eBooks · doi:10.1007/978-94-007-5958-9 · Cited by 6
Drug Development Against Metastatic Cancers.
Wang, C., & Huang, S. (2017) · PubMed Central · Cited by 5
Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer
Jensen, G. L., Tang, C. Z., Hess, K. R., Liao, Z. X., & Gomez, D. R. (2017) · Clinical & Experimental Metastasis · doi:10.1007/s10585-017-9850-1 · Cited by 5

Authors: Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., McBride, D. J., Varela, I., Nik-Zainal, S. A., Leroy, C., Jia, M., Menzies, A., Butler, A. P., Teague, J. W., Griffin, C. A., Burton, J., Swerdlow, H., Quail, M. A., Stratton, M. R., Iacobuzio-Donahue, C., & Futreal, P. A.
Affiliations: University of Cambridge (GB)
Johns Hopkins University (US)
Wellcome Sanger Institute (GB)
Institute of Cancer Research (GB)
Corresponding author: Futreal, P. Andrew
ORCID: Campbell, Peter J.
Yachida, Shinichi
Pleasance, Erin D.
Latimer, Calli
McLaren, Stuart
McBride, David J.
Varela, Ignacio
Jia, Mingming
Menzies, Andrew
Teague, Jon W.
Swerdlow, Harold
Quail, Michael A.
Stratton, Michael R.
Futreal, P. Andrew
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2010-10
Volume: 467
Issue: 7319
Pages: 1109-1113
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09460
PMC: PMC3137369
OpenAlex: W2066254965
Cited by: 1,317
References: 30
Citations by year: 2026: 10 · 2025: 31 · 2024: 33 · 2023: 51 · 2022: 47 · 2021: 86 · 2020: 69 · 2019: 72 · 2018: 75 · 2017: 117 · 2016: 104 · 2015: 119 · 2014: 153 · 2013: 109 · 2012: 135
FWCI: 34.92
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Skip Viragh Foundation
Uehara Memorial Foundation
Wellcome Trust (077012/Z/05/Z, 088340, 093867, WT088340MA)
National Institutes of Health
National Cancer Institute (R01CA140599, K08CA106610, CA140599, CA106610)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: pancreatic cancer, metastasis, genomic instability, chromosomal rearrangements, clonal evolution, telomere dysfunction, G1/S checkpoint, copy number alterations, tumor progression, early detection, therapeutic target, interpatient heterogeneity, tumour dissemination, somatic mutations, GATA4, GATA3
MeSH terms: Adenocarcinoma, Cell Cycle, Clone Cells, DNA Mutational Analysis, Humans, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Organ Specificity, Pancreatic Neoplasms, Mutagenesis, Telomere, Disease Progression, Cell Lineage, Evolution, Molecular, Genomic Instability, Genes, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks